Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Operating Leases (2019 - 2025)

ImmunityBio (IBRX) has disclosed Operating Leases for 7 consecutive years, with $41.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 5.36% to $41.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $41.4 million, a 5.36% decrease, with the full-year FY2024 number at $34.8 million, down 12.82% from a year prior.
  • Operating Leases was $41.4 million for Q3 2025 at ImmunityBio, up from $40.6 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $50.9 million in Q3 2022 to a low of $16.6 million in Q1 2021.
  • A 5-year average of $40.5 million and a median of $41.0 million in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: skyrocketed 235.24% in 2021, then fell 16.7% in 2023.
  • ImmunityBio's Operating Leases stood at $37.1 million in 2021, then grew by 29.36% to $48.0 million in 2022, then decreased by 16.7% to $39.9 million in 2023, then decreased by 12.82% to $34.8 million in 2024, then grew by 19.02% to $41.4 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Operating Leases are $41.4 million (Q3 2025), $40.6 million (Q1 2025), and $34.8 million (Q4 2024).